Elevated CA 19-9: Pancreatic or Stomach Cancer?

Short Answer

An elevated CA 19-9 alone does not establish a cancer diagnosis. Bile duct obstruction, pancreatitis, liver diseases and some benign conditions also raise this value. According to the 2010 report of the European Group on Tumor Markers (EGTM), the test's sensitivity and specificity are insufficient for early diagnosis. That is why CA 19-9 is not a screening test; your result is interpreted according to the laboratory reference range on your report and your symptoms.

How does it appear on your report?

• Test name: On reports it appears as "CA 19-9", "CA19-9" or "carbohydrate antigen 19-9".
• Unit: The Turkish Ministry of Health's Test Measurement Units (Version 2) uses U/mL for serum and plasma CA 19-9.
• e-Nabız: In the "Tahlillerim" (My Tests) section of e-Nabız (Türkiye's national health record app), the result is listed together with the laboratory's reference value. Values outside the reference range are shown in color. With the chart icon you can see your older results side by side.
• Reference range and decision limit: Under the Ministry's decision limit procedure, the laboratory specialist may add a method-dependent decision limit. Decision limits are marked with an asterisk (*) on the report and explained at the bottom of the report.

Red does not mean "cancer". It only shows that the value is outside that laboratory's range.

Normal value and reference range

Situation	Value	What does it mean?
Upper limit used in most studies	37 U/mL	Values below this are considered "normal"
Sensitivity for pancreatic cancer in a person with symptoms	79–81%	The value may not rise in about 1 in every 5 people with cancer
Specificity in a person with symptoms	82–90%	It is also high in some people who do not have cancer
Positive predictive value in screening people without symptoms	0.5–0.9%	Cancer is found in fewer than 1 in 100 people with a high result
Lewis-negative blood group trait	5–10% of the population	Cannot produce CA 19-9; the value stays low even if cancer is present

Source: Ballehaninna and Chamberlain, Journal of Gastrointestinal Oncology, 2012.

The reference range covers 95% of healthy people; about 1 in 20 healthy people may fall slightly outside the range. The upper limit may vary from laboratory to laboratory depending on the measurement method used. Use the limit on your own report as the basis.

Screening results clearly show this problem. In a large screening study, CA 19-9 was checked in 70,940 people without symptoms. Of the 1,063 people with a high value, pancreatic cancer was found in only 4.

What does it mean if it is high?

Causes are listed from common and benign to serious. Your doctor decides which one applies based on your symptoms and other tests.

• Bile duct obstruction and jaundice: Gallstones and bile duct inflammation (cholangitis) are among the most common benign causes. In obstructive jaundice, false-positive rates of 10–60% have been reported.
• Drop once the obstruction is relieved: In one study, after bile flow was restored the value fell in 41 of 42 patients with benign disease. In malignant obstruction, it fell in about half of the patients.
• Pancreatic inflammation and cysts: In acute and chronic pancreatitis, CA 19-9 rises in 10–50% of cases.
• Liver diseases: Cirrhosis, hepatitis, liver cysts and abscesses can increase the value.
• Other benign conditions: Ovarian cysts, heart failure, Hashimoto's thyroiditis, rheumatoid arthritis, diverticulitis and bronchitis have been reported.
• Digestive system cancers: It can rise in cancers of the pancreas, bile ducts, stomach, esophagus and colon.

CA 19-9 is not a stomach-specific test. Stomach cancer can also raise the value, but the stomach is evaluated by endoscopy. The pancreas is examined with imaging methods.

CA 19-9 is elevated in only 80–85% of patients with pancreatic cancer. This means a normal result does not completely rule out the disease either.

What does it mean if it is low?

A low or unmeasurably small CA 19-9 usually does not indicate a problem. In Lewis-negative people the body cannot produce this molecule. In these people the test does not rise even if cancer is present. So if symptoms persist, a normal result alone is not reassurance.

Read together

• CA 19-9 high, bilirubin and ALP/GGT also high: Suggests an obstruction of bile flow. Imaging such as ultrasound is done first. Interpretation is easier if CA 19-9 is rechecked after the obstruction is relieved.
• CA 19-9 high, amylase or lipase high, abdominal pain present: The possibility of pancreatitis comes to the fore. In this picture, CA 19-9 is not read as a cancer indicator.
• CA 19-9 and CEA ordered together: Neither is a screening test. The NACB 2008 guideline recommends CEA for post-diagnosis follow-up in colorectal cancer; for screening, it points to the fecal occult blood test.
• CA 19-9 normal but weight loss and jaundice present: Even if the test is normal, the symptoms should be evaluated promptly. Lewis negativity and tumors that do not raise the marker can explain this situation.
• Rising during treatment of known pancreatic cancer: Suggests the disease is progressing. According to the ASCO recommendation, this should be confirmed with other tests.

Preparation before the test

• Biotin (B7) supplements: According to the Ministry of Health's Total Testing Process Guide, high-dose biotin can lead to false results in immunochemical tests. Waiting at least 8 hours is recommended for those taking 5–10 mg a day, and 72 hours for those taking 100 mg a day or more. If you take supplements, tell the laboratory.
• Measurement while jaundiced: Bile obstruction can artificially raise the value. Your doctor may ask for a repeat measurement after the obstruction is relieved.
• Follow-up measurements: Because there can be differences between methods, have serial measurements done at the same laboratory if possible.
• Medications: Do not stop the medications you use on your own; discuss preparation with your doctor.

Which doctor, which test?

• A single high value in a person without symptoms: Family physician. Usually a repeat measurement and liver tests such as bilirubin, ALP, GGT, ALT and AST are ordered.
• Jaundice, itching, dark urine, pale stools: Gastroenterology. Abdominal ultrasound and, if needed, CT, MRI or MR cholangiography are planned.
• Weight loss, loss of appetite, abdominal pain radiating to the back: Gastroenterology or general surgery. The pancreas is examined with contrast-enhanced CT or MRI.
• Difficulty swallowing, signs of stomach bleeding, early satiety: Gastroenterology. Upper gastrointestinal endoscopy is performed.
• Follow-up of known cancer: Medical oncology. According to the ASCO 2006 recommendation, in advanced pancreatic cancer CA 19-9 can be measured every 1–3 months during treatment.
• Family history of pancreatic cancer or a hereditary syndrome: Gastroenterology and medical genetics. The USPSTF screening recommendation does not cover this high-risk group; the follow-up plan is individualized.

In Türkiye

• Not part of national screening: The national cancer screenings run by HSGM (the Ministry of Health General Directorate of Public Health) and KETEMs (Cancer Early Diagnosis, Screening and Training Centers) cover breast, cervical and colorectal cancer. For the breast, mammography is done every 2 years at ages 40–69; for the cervix, an HPV-DNA test every 5 years at ages 30–65. For the colon, a fecal occult blood (FIT) test is done every 2 years at ages 50–70. There is no national screening program for the pancreas or stomach; CA 19-9 is not part of these programs.
• Check-up packages: CA 19-9 is not recommended for screening in people without symptoms. The USPSTF 2019 recommendation is against pancreatic cancer screening in adults without symptoms.
• Reporting unit: The Ministry's Test Measurement Units document sets U/mL as the standard unit for CA 19-9. When comparing results from different laboratories, check the unit and reference range.
• Follow-up in e-Nabız: The chart on the Tahlillerim screen lets you see how the same test changes over time. The trend is more meaningful than a single value.
• Biotin warning: The Ministry's 2024 Total Testing Process Guide specifically stresses that biotin can interfere with immunological tests.

When should you seek urgent care?

• If yellowing of the eyes or skin is accompanied by fever and chills, go to the emergency department the same day. This picture may be bile duct inflammation.
• If you have severe abdominal pain radiating to the back and repeated vomiting, go to the emergency department. If there is confusion or fainting, call 112 (the emergency number in Türkiye).
• If you vomit blood or pass black, tar-like stools, call 112 or go to the nearest emergency department.
• If the laboratory has called you because of a critical value in another test from the same panel, do what you are told without delay.
• If rapid weight loss and jaundice occur together, be sure to see a doctor within a few days.

Related tests

• Lab Test Guide: all tests
• When should liver enzymes be taken seriously?
• CRP, sedimentation rate and procalcitonin: inflammation tests
• Thyroid tests: TSH, T3, T4 and anti-TPO
• How to read urinalysis results

What has changed? (October 2026)

• New page. Based on the EGTM 2010 pancreatic cancer marker report, the NACB 2008 tumor marker guideline and the USPSTF 2019 screening recommendation.
• Information on Türkiye is consistent with the HSGM national cancer screening standards and the Ministry of Health Test Measurement Units Version 2.

Sources

• Duffy MJ, Sturgeon C, Lamerz R et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010;21:441-447. https://doi.org/10.1093/annonc/mdp332 (accessed October 2, 2026)
• Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 2012;3(2):105-119. https://doi.org/10.3978/j.issn.2078-6891.2011.021 (accessed October 2, 2026)
• Sturgeon CM, Duffy MJ, Stenman UH et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-e79. https://doi.org/10.1373/clinchem.2008.105601 (accessed October 2, 2026)
• Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327. https://doi.org/10.1200/JCO.2006.08.2644 (accessed October 2, 2026)
• US Preventive Services Task Force. Pancreatic Cancer: Screening. Recommendation, August 2019. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/pancreatic-cancer-screening (accessed October 2, 2026)
• T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Kanser Taramaları. Current page. https://hsgm.saglik.gov.tr/tr/kanser-taramalari (accessed October 2, 2026)
• T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Tıbbi Biyokimya Toplam Test Süreci Rehberi. May 2024, Publication No 1287. https://dosyamerkez.saglik.gov.tr/Eklenti/48692/0/tibbi-biyokimya-toplam-test-sureci-rehberipdf.pdf (accessed October 2, 2026)
• T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Test Ölçüm Birimleri, Versiyon 2. 15.09.2021. https://dosyamerkez.saglik.gov.tr/Eklenti/41467/0/test-olcum-birimleri-versiyon-2-pdfpdf.pdf (accessed October 2, 2026)
• T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Karar Sınırı (Eşik Değer), Kritik Değer (Panik Değer) ve Ölçüm Birimlerinin Harmonizasyonu Prosedürü. 22.09.2020. https://dosyamerkez.saglik.gov.tr/Eklenti/15143/0/karar-siniri-esik-deger-kriek42009846pdf.pdf (accessed October 2, 2026)
• T.C. Sağlık Bakanlığı. e-Nabız Kullanım Kılavuzu V2.1. 31.05.2025. https://enabiz.gov.tr/document/User_Manual.pdf (accessed October 2, 2026)